Proteome Sciences
PRM · AIM · Health Care · mcap £5.3m · 1.4p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 16 Sep 26 | Board change | Appointment of Non-Executive Director
Proteome Sciences plc (AIM:PRM) is pleased to announce the appointment of Helen Spice FCA as an independent non-executive director of the Company, with immediate effect. |
+0.0% |
| 16 Sep 26 | Results | Interim Results H1 2026
Interim results for the six months ended 30 June 2026 |
+0.0% |
| 15 Sep 26 | Further GCLP Chemoproteomics contract secured
As initially announced in June this year, Proteome Sciences plc (AIM:PRM) is pleased to now confirm that the Company has secured the expected significant clinical contract for its chemoproteomics platform. |
+3.6% | |
| 22 Jun 26 | Target engagement/chemoproteomics contract
Proteome Sciences plc (AIM:PRM) is pleased to announce that the Company has secured a further significant clinical contract connected to its target engagement/chemoproteomics platform. |
−0.7% | |
| 01 Jun 26 | Board change | Directorate Change
The directors of Proteome Sciences plc announce that Dr Ian Pike has decided to step down from his executive role as Chief Scientific Officer with effect from 31 May 2026. |
+0.7% |
| 14 May 26 | Annual General Meeting Statement
At the Company's Annual General Meeting ("AGM") being held today at 12.00 noon, the Chairman, Christopher Pearce, made the following statement: |
+0.0% | |
| 15 Apr 26 | Results | Final Results
Final results for the year ended 31 December 2025 |
−4.8% |
| 28 Jan 26 | Fundraise | Result of Oversubscribed Retail Offer
596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). |
−2.3% |
| 26 Jan 26 | Fundraise | Retail Offer to raise up to £60,000
Proteome Sciences (AIM: PRM) is pleased to announce the launch of an offer to retail investors in the UK through BookBuild (the "Retail Offer") of up to 3,428,571 new ordinary shares of one penny each in the capital of t |
−41.0% |
| 26 Jan 26 | Fundraise | £840,000 Fundraise and Retail Offer
This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any investment decision in respect of Proteome Sciences plc |
−41.0% |
| 06 Jan 26 | Two Further Substantial Contracts for PRM
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. |
+26.3% | |
| 08 Dec 25 | Substantial contract for Proteome Sciences
Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. |
−9.2% | |
| 25 Nov 25 | Appointment of Nominated Adviser and Broker
Proteome Sciences (AIM:PRM), is pleased to announce that SP Angel Corporate Finance LLP has been appointed as the Company's new Nominated Adviser and sole Broker with immediate effect. |
+2.1% |
Company filings. Not investment advice.